Want to invest in an industry that consistently outperforms the S&P 500? Here are three stocks to consider.
News & Analysis: BeiGene
Investors cheered another big investment in the Chinese biotech.
BeiGene and Vertex Pharmaceuticals aren't nearly as expensive as you may think.
Chinese drugmaker BeiGene would compete directly with Merck's cancer superdrug.
The FDA was in a big hurry to make these new therapies available for patients who need them.
Here's why the FDA recently approved five new drugs way ahead of schedule.
BeiGene and Zai Lab offer two ways to invest in what could be a big opportunity.
One of America's largest biotechs will join hands with an industry leader in the rapidly expanding Chinese market.
A short-seller report weighed on the Chinese biotech's shares last month.
China's biopharma gem drifted lower in the first half of 2019, but there's no identifiable explanation or cause for concern.